We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Futura Medical
Commercialisation deal for China and SE AsiaNexstim
A positive start to the 2020-24 strategyNexstim
Promising results for severe depression pilot studyAllergy Therapeutics
Record revenues demonstrate resilience of operationsMaxCyte
Better visibility brings future into focusMaxCyte
US institutional private placing raises £40mScancell
H121 results highlight shift to delivery and executionRedx Pharma
FY20 results highlight extent of progress madeAllergy Therapeutics
Robust growth, pipeline progress, and cash positionAllergy Therapeutics
Imperial peanut allergy biomarker study underway